| Literature DB >> 28575475 |
Lisa Kronbichler1, Melanie Tschernegg2,3, Anna Isabel Martin2,3, Matthias Schurz2,3, Martin Kronbichler1,2,3.
Abstract
Social cognition abilities are severely impaired in schizophrenia (SZ). The current meta-analysis used foci of 21 individual studies on functional abnormalities in the schizophrenic brain in order to identify regions that reveal convergent under- or over-activation during theory of mind (TOM) tasks. Studies were included in the analyses when contrasting tasks that require the processing of mental states with tasks which did not. Only studies that investigated patients with an ICD or DSM diagnosis were included. Quantitative voxel-based meta-analyses were done using Seed-based d Mapping software. Common TOM regions like medial-prefrontal cortex and temporo-parietal junction revealed abnormal activation in schizophrenic patients: Under-activation was identified in the medial prefrontal cortex, left orbito-frontal cortex, and in a small section of the left posterior temporo-parietal junction. Remarkably, robust over-activation was identified in a more dorsal, bilateral section of the temporo-parietal junction. Further abnormal activation was identified in medial occipito-parietal cortex, right premotor areas, left cingulate gyrus, and lingual gyrus. The findings of this study suggest that SZ patients simultaneously show over- and under-activation in TOM-related regions. Especially interesting, temporo-parietal junction reveals diverging activation patterns with an under-activating left posterior and an over-activating bilateral dorsal section. In conclusion, SZ patients show less specialized brain activation in regions linked to TOM and increased activation in attention-related networks suggesting compensatory effects.Entities:
Keywords: fMRI; mentalizing; psychosis
Mesh:
Year: 2017 PMID: 28575475 PMCID: PMC5737081 DOI: 10.1093/schbul/sbx073
Source DB: PubMed Journal: Schizophr Bull ISSN: 0586-7614 Impact factor: 9.306
Clinical Description of Patients With Schizophrenia Included in Theory of Mind Studies
| Reference | Mean Age (SD) Patients/Controls | Gender M/F Patients; M/F Controls | Symptom Scales Mean Scores (SD) | Diagnosis/Recruitment/ Illness Duration (SD) | Medication Dose (mg): Mean (SD) |
|---|---|---|---|---|---|
| Brüne et al19 | 27.9 (6.6)/26.5 (5.3) | 3/6; 4/9 | PANSS + 16.67 (5.7); PANSS − 15.67 (8.8) | First episode ( | NLP: 244.44 (173) |
| Walter et al23 | 29.5 (6.0)/24.7 (2.6) | 6/6; 6/6 | PANSS + 17.75 (5.0); PANSS − 19.41 (3.9) | Inpatients; duration: 6.3 (5.2) | N/A |
| Benedetti et al25 | 37.2 (10.23)/35.1 (9.95) | 14/10; 7/13 | PANSS + 16 (4.58); PANSS − 21.66 (5.42) | Stable outpatients; first episode ( | Clozapine |
| Lee et al31 | 26 (4.3)/25.8 (2.2) | 7/8; 9/9 | PANSS + 13.1 (5.1); PANSS − 15.4 (4.1) | Stable outpatients; inpatients; duration: 4.6 (3.4) | NLP: 422.1 (237) |
| Lee et al24 | 38.3 (10.7)/42.5 (7.7) | 10/2; 10/3 | N/A | DSM-IV (SCID-P); stable outpatients | N/A |
| Pedersen et al18 | 29 (8.2)/29.9 (8.8) | 9/6; 9/5 | PANSS + 10.9 (2.8); PANSS − 14.9 (5.4) | Stable outpatients; duration: 5.5 (6.3) | NLP: 629.6 (395) |
| Eack et al32 | 27.8 (6.61)/26.50 (5.82) | 14/6; 13/7 | N/A | DSM-IV; stable outpatients; duration: 4.85 (3.18) | NLP: 308.08 (235.89) |
| Varga et al33 | 37.95 (9.06)/33.96 (8.51) | 9/12; 10/14 | PANSS + 13.81 (3.2); PANSS − 17.00 (5.4) | DSM-IV; remission; duration: 11.95 (8.45) | Amisulpiride |
| Harvey et al34 | 42.4 (11.8)/42.9 (8.6) | 13/2; 13/2 | SANS 27.1 (9.7) | DSM-IV (SCID-P); psychiatrically stable | NPL: 210 (142) |
| Bedford et al35 | 39 (11)/31 (9) | 7/4; 3/5 | N/A | DSM-IV-TR; inpatients = 4, outpatients = 7; remission; duration: 12 (8) | Anti-psychotic medication |
| Rapp et al36 | 28.1 (N/A)/32.9 (N/A) | 0/15 | PANSS + 17.4 (N/A); PANSS − 16.00 (N/A) | DSM-IV; inpatients; clinically stable | NPL: 516.0 (237) |
| Russell et al37 | 36 (9)/ | 5/0; 7/0 | N/A | DSM-IV; inpatients = 4, outpatients = 7; duration: 13 (7) | N/A |
| Brüne et al38 | 6.8 (5.5)/8.8 (4.1) | 15/7; 16/9 | PANSS + 18.2 (4.8); PANSS − 21.2 (7.1) | DSM-IV; inpatients; duration: 3.3 (3.7) | NPL: 475 (429) |
| Brunet et al21 | 31 (6.5)/23.3 (1.68) | 7/0; 8/0 | N/A | DSM-IV; outpatients | Loxapine |
| Mier et al39 | 34.25 (6.95)/37.0 (8.18) | 11/5; 11/5 | SAPS 1.5 (1.37); SANS 7.94 (2.86) | DSM-IV; outpatients | NPL: 901.59 (647.1) |
| Andreasen et al20 | 32.5 (11.0)/26.5 (6.4) | 14/4; 6/7 | SAPS 2.8 (N/A); SANS 2.1 (N/A) | DSM-IV; outpatients; duration: 8.96 (9.3) | No medication |
| Ciaramidaro et al40 | range: 14–32/ range:15–27 | 14/4; 19/4 | N/A | DSM-IV; inpatients; duration: 6.25 (3.5) | N/A |
| Das et al22 | 34.5 (8.4)/33.5 (8.4) | 20/0; 19/0 | PANSS + 10.1 (3.0); PANSS − 18.2 (5.2) | DSM-IV; duration: 9.4 (6.5) | Lithium |
| Dodell et al41 | 38.8 (9.7)/32.4 (12.1) | 12/8; 12/6 | SAPS 3.1 (N/A); SANS 1.7 (N/A) | DSM-IV; inpatients; duration: 17.1 (12.2) | NPL: 501.6 (402.8) |
| Pauly et al42 | 36.23 (9.46)/34.46 (8.58) | 7/6; 7/6 | SAPS 4.3 (N/A); SANS 7.0 (N/A) | DSM-IV; remission; duration: 12 (6.93) | N/A |
| Lee et al43 | 31.7 (7.3)/30.5 (8.8) | 13/1; 13/1 | SAPS 6.9 (2.6); SANS 7.6 (2.8) | DSM-IV; inpatients | NPL: 354.3 (N/A) |
Note: Unless otherwise specified, neuroleptic dose (NPL) is expressed in chloropormazine equivalents and duration of illness is reported in years. N/A, data not available; PANSS, Positive and Negative Symptom Scale; SANS, Scale for the Assessment of Negative Symptoms; SAPS, Scale for the Assessment of Positive Symptoms.
Fig. 1.Slices illustrate convergent under-activation (slices -25, -2, 20) and over-activation (slice 38) in patients compared to healthy controls at a voxel-level (height) threshold of P < .005 (uncorrected) and a cluster-level (extent) threshold of 10 voxels.
Results of the meta-analysis of functional brain abnormalities during theory of mind
| Tasks in Schizophrenia | ||||||
|---|---|---|---|---|---|---|
| Label |
|
|
| SDM-Z | Voxels | JK |
|
| ||||||
| Medial prefrontal cortex | −2 | 52 | 18 | 1.612 | 1573 | 20/21 |
| Frontal medial cortex | −4 | 40 | −10 | |||
| Paracingulate gyrus | −2 | 42 | −6 | |||
| R premotor cortex | 54 | −14 | 18 | 1.728 | 1101 | 21/21 |
| Central opercular cortex | 48 | −6 | 4 | |||
| Postcentral gyrus | 48 | −10 | 28 | |||
| Precentral gyrus | 56 | −4 | 34 | |||
| Medial occipitoparietal | −4 | −76 | 14 | 1.158 | 128 | 19/21 |
| R lingual gyrus | 12 | −58 | 2 | 1.221 | 99 | 19/21 |
| L orbito-frontal cortex | −30 | 22 | −24 | 1.109 | 30 | 14/21 |
| L lateral occipitotemporal | −48 | −72 | 22 | 1.124 | 27 | 18/21 |
| L cingulate gyrus | −18 | −44 | −2 | 1.084 | 24 | 18/21 |
|
| ||||||
| L inferior parietal cortex | −42 | −48 | 38 | −1.697 | 486 | 21/21 |
| R inferior parietal cortex | 58 | −40 | 40 | −1.114 | 405 | 19/21 |
Note: L, left; R, right; JK, jackknife analysis (number of subsamples that replicate the finding).
Subclusters are reported for cluster sizes above 1000 voxels only.
Fig. 2.Significant cluster revealed by the filtered subgroup analyses of the SDM group-comparison option. (A1-C2) To facilitate the comparison with the main meta-analysis, the results of the overall meta-analysis are indicated. Significant cluster (voxel level threshold P < .005, cluster extent = 10) of the subgroup analyses and the overlap between regions obtained from the subgroup analyses and the overall meta-analysis are shown as indicated by the color legend.
Accordance Between Clusters of Subgroups With Main Meta-Analysis
| Task Type | Medial Prefrontal Cortex | R Premotor Cortex | L Orbito- frontal Cortex | Medial Occipito- parietal | R Lingual Gyrus | L Lateral Occipito- temporal | L Cingulate Gyrus | L Inferior Parietal Cortex | R Inferior Parietal Cortex |
|---|---|---|---|---|---|---|---|---|---|
| Visual | 22.9 | 10.8 | 2.3 | 32.0 | |||||
| Verbal | 20.5 | 11.5 | 21.9 | ||||||
| Cognitive | 13.7 | 16.3 | 69.4 | 20.4 | 4.0 | 28.1 | |||
| Affective | 25.4 | 8.1 | 1.6 | 5.5 | |||||
| Implicit | 19.3 | 26.9 | 24.4 | 14.2 | |||||
| Explicit | 15.0 | 8.0 | 18.6 | 7.4 | 22.1 | ||||
| Σ | 4/6 | 4/6 | 3/6 | 2/6 | 2/6 | 1/6 | 3/6 | 5/6 | 2/6 |
Note: Regions marked with a number revealed significant over-/under-activation in the respective subgroup at a threshold of P < .005, voxel extent 10. The specific number indicates to what extent (percent) the clusters of the task-specific analyses overlap with the clusters of the main analysis.